Ferrous Sulfate
NDC 76413-308
Product Information
Ferrous Sulfate is a UNAPPROVED DRUG OTHER-approved product labeled by Central Texas Community Health Centers. This medication is an iron supplement used to treat or prevent low blood levels of iron (such as those caused by anemia or pregnancy). It is supplied as a red product. This product entry covers the primary NDC 76413-308 and its associated package configuration. This profile includes active and inactive ingredient UNII references and FDA labeling data.
Primary Identification
Labeler & Regulatory Data
Marketing Timeline
Product Characteristics
Code Structure Chart
Product Details
What is NDC 76413-308?
What are the uses of this product?
Which are the associated UNII Codes?
The UNII codes for the active ingredients in this product are:
- FERROUS SULFATE (UNII: 39R4TAN1VT)
- FERROUS CATION (UNII: GW89581OWR) (Active Moiety)
Which are the Inactive Ingredients associated UNII Codes?
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:
- CELLULOSE, MICROCRYSTALLINE (UNII: OP1R32D61U)
- DIBASIC CALCIUM PHOSPHATE DIHYDRATE (UNII: O7TSZ97GEP)
- CROSCARMELLOSE SODIUM (UNII: M28OL1HH48)
- SODIUM STARCH GLYCOLATE TYPE A POTATO (UNII: 5856J3G2A2)
- HYPROMELLOSES (UNII: 3NXW29V3WO)
- STEARIC ACID (UNII: 4ELV7Z65AP)
- POLYETHYLENE GLYCOL 400 (UNII: B697894SGQ)
- FD&C RED NO. 40 (UNII: WZB9127XOA)
- MAGNESIUM STEARATE (UNII: 70097M6I30)
- TITANIUM DIOXIDE (UNII: 15FIX9V2JP)
- POLYETHYLENE GLYCOL 8000 (UNII: Q662QK8M3B)
- CARNAUBA WAX (UNII: R12CBM0EIZ)
What is the NDC to RxNorm Crosswalk for this product?
- RxCUI: 310325 - ferrous sulfate 325 MG (iron 65 MG) Oral Tablet
- RxCUI: 310325 - ferrous sulfate 325 MG Oral Tablet
- RxCUI: 310325 - ferrous sulfate 324 MG (iron 65 MG) Oral Tablet
- RxCUI: 310325 - FESO4 325 MG Oral Tablet
* Please review the full disclaimer at the bottom of this page.